The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Hartmut Porst

Private Practice of Urology and Andrology

Neuer Jungfernstieg 6a

20354 Hamburg



Name/email consistency: high



  • Private Practice of Urology and Andrology, Neuer Jungfernstieg 6a, 20354 Hamburg, Germany. 2000 - 2012
  • Private Urological Practice, Hamburg, Germany. 2001 - 2010


  1. Effects of once-daily tadalafil on treatment satisfaction, psychosocial outcomes, spontaneous erections, and measures of endothelial function in men with erectile dysfunction but naive to phosphodiesterase type 5 inhibitors. Porst, H., Brock, G.B., Kula, K., Moncada, I., Montorsi, F., Basson, B.R., Kinchen, K., Aversa, A. J. Androl. (2012) [Pubmed]
  2. Chronic PDE-5 inhibition in patients with erectile dysfunction - a treatment approach using tadalafil once-daily. Porst, H., Hell-Momeni, K., Büttner, H. Expert. Opin. Pharmacother (2012) [Pubmed]
  3. Durability of response following cessation of tadalafil taken once daily as treatment for erectile dysfunction. Porst, H., Glina, S., Ralph, D., Zeigler, H., Wong, D.G., Woodward, B. J. Sex. Med (2010) [Pubmed]
  4. Standards for clinical trials in male sexual dysfunctions. Porst, H., Vardi, Y., Akkus, E., Melman, A., Park, N.C., Seftel, A.D., Teloken, C., Wyllie, M. J. Sex. Med (2010) [Pubmed]
  5. Baseline characteristics and treatment outcomes for men with acquired or lifelong premature ejaculation with mild or no erectile dysfunction: integrated analyses of two phase 3 dapoxetine trials. Porst, H., McMahon, C.G., Althof, S.E., Sharlip, I., Bull, S., Aquilina, J.W., Tesfaye, F., Rivas, D.A. J. Sex. Med (2010) [Pubmed]
  6. Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Porst, H., McVary, K.T., Montorsi, F., Sutherland, P., Elion-Mboussa, A., Wolka, A.M., Viktrup, L. Eur. Urol. (2009) [Pubmed]
  7. Vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Porst, H., Sandner, P., Ulbrich, E. Curr. Urol. Rep (2008) [Pubmed]
  8. Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. Porst, H., Rajfer, J., Casabé, A., Feldman, R., Ralph, D., Vieiralves, L.F., Esler, A., Wolka, A.M., Klise, S.R. J. Sex. Med (2008) [Pubmed]
  9. Development and validation of the quality of erection questionnaire. Porst, H., Gilbert, C., Collins, S., Huang, X., Symonds, T., Stecher, V., Hvidsten, K. J. Sex. Med (2007) [Pubmed]
  10. The Premature Ejaculation Prevalence and Attitudes (PEPA) survey: prevalence, comorbidities, and professional help-seeking. Porst, H., Montorsi, F., Rosen, R.C., Gaynor, L., Grupe, S., Alexander, J. Eur. Urol. (2007) [Pubmed]
  11. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5mg and 10mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Porst, H., Giuliano, F., Glina, S., Ralph, D., Casabé, A.R., Elion-Mboussa, A., Shen, W., Whitaker, J.S. Eur. Urol. (2006) [Pubmed]
  12. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Porst, H., Sharlip, I.D., Hatzichristou, D., Rubio-Aurioles, E., Gittelman, M., Stancil, B.N., Smith, P.M., Wilkins, H.J., Pommerville, P. Eur. Urol. (2006) [Pubmed]
  13. IC351 (tadalafil, Cialis): update on clinical experience. Porst, H. Int. J. Impot. Res. (2002) [Pubmed]
  14. The efficacy and tolerability of vardenafil, a new, oral, selective phosphodiesterase type 5 inhibitor, in patients with erectile dysfunction: the first at-home clinical trial. Porst, H., Rosen, R., Padma-Nathan, H., Goldstein, I., Giuliano, F., Ulbrich, E., Bandel, T. Int. J. Impot. Res. (2001) [Pubmed]
  15. Current perspectives on intracavernosal pharmacotherapy for erectile dysfunction. Porst, H. Int. J. Impot. Res. (2000) [Pubmed]
WikiGenes - Universities